The opium alkaloid noscapine as a low toxic tubulin stabiler was reported in previous studies that it inhibits the growth of several human and murine neoplasms including lymphoma , thymoma , melanoma and breast cancer with no significant toxic effects in tissues with active cell proliferation such as bone marrow , spleen and intestine. We reported that daily oral noscapine treatment (300 mg/Kg) administered to PC 3 human prostate cancer-bearing immunodeficient mice (n=10) revealed a significant reduction of tumor volume. Tumor inhibition rate of 60%. Total tumor weight was 0.42+/- 0.23 in noscapine treated group versus 0.97 +/- 0.31 in the vehicle treated group (P< 0.001) This was achieved with no identifiable toxicity. Furthermore, noscapine treatment resulted in a slow incidence of metastasisi in the experimental animals compare with that of the vehicle treated animals. The metastsis rate was 30% in the noscapine treated group and 90% in the vehicle treated group, respectively (P< 0.05). Our findings have shown that oral administration fo noscapine is effective agains the primary tumor growth and lymphatic metastasis on PC 3 human prostate cancer. These data warrant additional investigations of nontoxic therapeutic potential of noscapine for malignant disease, especially prostate cancer.
Zion 5143 Ave San Diego, CA 92120
619-851-0001
dr@barken.com
© Copyright 2005 to 2017, The Prostate Cancer Research and Education Foundation (PCREF)